Fifty years ago, a cancer diagnosis meant roughly a coin-flip chance of surviving five years. Today, **seven in ten cancer patients** reach that milestone. The American Cancer Society's landmark 2026 statistics report documents one of the most quietly extraordinary achievements in modern medicine.
The report, published in *CA: A Cancer Journal for Clinicians*, confirms that the **five-year relative survival rate for all cancers combined** has reached **70%** — measured for patients diagnosed between 2015 and 2021. In the mid-1970s, that figure stood at just 49%.
That 21-percentage-point improvement represents millions of lives saved — and the gains are accelerating.
**The Cancers Where Progress Is Most Dramatic**
The report highlights extraordinary turnarounds for cancer types that were once almost uniformly fatal:
- **Metastatic melanoma:** Five-year survival has climbed from 16% to 35% in just 25 years, driven almost entirely by immune checkpoint inhibitors — drugs that take the brakes off the immune system and allow it to recognise and destroy cancer cells. - **Lung cancer:** Historically the deadliest cancer by deaths, targeted therapies and immunotherapy have dramatically improved outcomes. Early detection through low-dose CT scans is catching cancers at curable stages. - **Myeloma:** Once considered incurable, this blood cancer now has a five-year survival that has roughly tripled since the early 1990s, thanks to novel drug combinations and stem cell transplants. - **Liver cancer:** Five-year survival has more than doubled over the past decade, driven by better surveillance, new targeted agents, and immunotherapy combinations. - **Childhood cancers:** The overall five-year survival for childhood cancer now exceeds 85% — a figure that would have seemed impossible in the 1970s.
**Three Revolutions Driving the Gains**
**1. Immunotherapy.** The development of checkpoint inhibitors unlocked a new approach: instead of attacking cancer cells directly with chemotherapy, these drugs help the patient's own immune system recognise and eliminate tumours. For some patients with metastatic melanoma, lung cancer, and bladder cancer, they have produced long-lasting remissions where no other treatment had succeeded.
**2. Targeted therapy.** Advances in genomics have allowed oncologists to identify the specific mutations driving a patient's cancer and choose drugs designed to block those exact pathways. The era of one-size-fits-all chemotherapy is giving way to precision medicine tailored to the individual tumour's biology.
**3. Early detection.** Lung cancer screening, improved colonoscopy rates, HPV vaccination reducing cervical cancer, and the emergence of multi-cancer early detection blood tests have all shifted the dial toward catching cancers at earlier, more treatable stages.
**1.9 Million Deaths Averted Since 1991**
The progress is most dramatically illustrated by another figure: since US cancer death rates peaked in 1991, the decline in cancer mortality has averted an estimated **4.1 million deaths**. That is 4.1 million people alive today — brothers, sisters, parents, children — who would have died from cancer had the mortality rates of 1991 persisted.
Overall cancer death rates have dropped 34% from their 1991 peak.
**The Work Still to Do**
The report is candid about what remains. Pancreatic cancer still has a five-year survival of only 13%. Brain cancer, oesophageal cancer, and late-stage lung cancer remain devastating. And survival gains have not been equally distributed — Black Americans, rural communities, and low-income patients continue to face significantly worse outcomes.
But the trajectory is unmistakable. From 49% to 70% in fifty years. And with mRNA cancer vaccines entering pivotal trials, CAR-T cell therapy expanding to new tumour types, and multi-cancer early detection tests approaching regulatory approval — the next fifty years may be even more remarkable. 💙
*Sources: American Cancer Society — Cancer Statistics 2026 · ScienceAlert · Cancer Network · pressroom.cancer.org*